Combination treatment for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a new combination of an immunotherapy drug (QL1706) and a vaccine for people with cervical cancer that has not improved, came back, or spread. It aims to see if this combination can help control the cancer better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has not been treated with systemic therapy (like chemotherapy or immunotherapy) before.
- A biopsy has confirmed your cancer is cervical cancer.
- You have at least one tumor that can be measured by scans, and it is not in an area previously treated with radiation unless it has clearly grown.
- You are generally well enough to be up and about (ECOG score 0 or 1).
- Your major organs (like blood, liver, kidneys) are functioning within required limits, and you do not have serious infections like active hepatitis B or C (or you agree to treatment for them).
- If you could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during the study and for 90 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
This trial tests a new immunotherapy drug (QL1706) for cervical cancer that has stopped responding to earlier PD-1 therapies. The goal is to see if this drug can help shrink tumors or slow down the cancer.
This trial tests a combination of two drugs for cervical cancer that has returned or spread after initial treatment. The drugs target cancer cells with a specific marker called HER2 and may help shrink tumors or slow their growth.
This trial tests a new drug (QL1706) combined with chemotherapy before the usual radiation therapy for locally advanced cervical cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests combining two immunotherapy drugs with chemotherapy and sometimes another drug called bevacizumab, followed by radiation and chemotherapy. It aims to see if this approach can better treat advanced cervical cancer.
This trial tests a new drug called QL706 combined with chemotherapy, with or without another drug called bevacizumab, for people with cervical cancer that has returned or spread and no longer responds to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Cervical Cancer Stage IVB trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.